Development of a decellularized liver matrix-based nanocarrier for liver regeneration after partial hepatectomy

Integrating carrier drug therapy with recent advances in liver tissue regeneration, this paper proposes a novel nanomedicine-based approach to drug delivery, with the aim of enhancing the regenerative capacity of hepatocytes and improving liver function after partial hepatectomy. The proposed decell...

Full description

Saved in:
Bibliographic Details
Published in:Journal of materials science 2023-10, Vol.58 (38), p.15162-15180
Main Authors: Chiu, Yu-Chuan, Huang, Kai-Wen, Lin, Yong-Heng, Yin, Wei-Rong, Hou, Yung-Te
Format: Article
Language:English
Subjects:
Albumin
albumins
Biocompatibility
Characterization and Evaluation of Materials
Chemistry and Materials Science
Classical Mechanics
Crystallography and Scattering Methods
Drug delivery systems
drug therapy
Drugs
Ethylenediaminetetraacetic acid
Hepatectomy
hepatocytes
Liver
Liver diseases
liver function
liver regeneration
Materials for Life Sciences
Materials Science
MPEG encoders
nanocarriers
Polymer Sciences
Regeneration (physiology)
Solid Mechanics
Tannic acid
tannins
Tissue engineering
tissue repair
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Integrating carrier drug therapy with recent advances in liver tissue regeneration, this paper proposes a novel nanomedicine-based approach to drug delivery, with the aim of enhancing the regenerative capacity of hepatocytes and improving liver function after partial hepatectomy. The proposed decellularized liver matrix provides excellent biocompatibility and similarity to natural liver components, while the molecules encapsulated in the carrier (tannic acid) promote liver regeneration. In in vitro cultures, the 0.001 mg/mL TA-mPEG-DLM group consistently outperformed the blank group in terms of albumin synthesis: Day 1 (11.1 ± 2.4 vs. 8.2 ± 0.7), Day 3 (5.8 ± 1.3 vs. 4.2 ± 0.4), and Day 5 (1.6 ± 0.3 vs. 1.2 ± 0.2) (μg/100% proliferation rate/well/day). In a liver-injured in vivo model, the 0.5 mg/mL TA-mPEG-DLM group outperformed the blank group in terms of relative liver weight: Day 3 (3.50 ± 0.09% vs. 3.22 ± 0.03%) and Day 7 (4.13 ± 0.21% vs. 3.72 ± 0.06%). Furthermore, the TA-mPEG-DLM group outperformed the blank group in terms of Ki-67 expression in hepatocytes on Day 7 (192.7 ± 34.1% vs. 150.4 ± 11.6%). Taken together, these findings indicate that the proposed drug delivery strategy is a promising approach to liver regeneration following partial hepatectomy with potential for clinical translation.
ISSN:0022-2461
1573-4803
DOI:10.1007/s10853-023-08971-w